Cardiotoxicity of Anti-Cancer Radiation Therapy: a Focus on Heart Failure.
Cardio-oncology
Cardiotoxicity
Heart failure
Radiation therapy
Thoracic malignancies
Journal
Current heart failure reports
ISSN: 1546-9549
Titre abrégé: Curr Heart Fail Rep
Pays: United States
ID NLM: 101196487
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
accepted:
06
12
2022
pubmed:
25
1
2023
medline:
4
3
2023
entrez:
24
1
2023
Statut:
ppublish
Résumé
As the percentage of patients achieving long-term survival following treatment of their cancer grows, it is increasingly important to understand the long-term toxicities of cancer-directed treatment. In this review, we highlight the recent findings regarding radiation-induced cardiotoxicity across multiple disease sites, with a particular focus on heart failure. Despite its relative lack of study historically, radiation-induced heart failure has now recently been implicated in several studies of breast cancer, lung cancer, esophageal cancer, and lymphoma as a non-trivial potential consequence of thoracic radiotherapy. Data regarding specific cardiac dosimetric endpoints relevant to cardiotoxicity continue to accumulate. Radiation-induced heart failure is a rare but significant toxicity of thoracic radiotherapy, that is likely underreported. Important areas for future focus include understanding the interplay between thoracic radiotherapy and concurrent cardiotoxic systemic therapy as well as development of potential mitigation strategies and novel therapeutics.
Identifiants
pubmed: 36692820
doi: 10.1007/s11897-023-00587-0
pii: 10.1007/s11897-023-00587-0
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
44-55Subventions
Organisme : NHLBI NIH HHS
ID : L30 HL149063
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL155890
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.